FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/01/079279 [Registered on: 23/01/2025] Trial Registered Prospectively
Last Modified On: 11/06/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   AN OBSERVATIONAL STUDY BETWEEN INTRATHECAL HYPERBARIC BUPIVACAINE 0.5 Percent 3.3cc WITH DEXMEDATOMEDINE 10 MICROGRAM VERSUS HYPERBARIC BUPIVACAINE 0.5 percent 3.3cc WITH NALBUPHINE 1 MG Intrathecally IN LOWER LIMB ORTHOPAEDIC SURGERIES 
Scientific Title of Study   A COMPARATIVE STUDY BETWEEN INTRATHECAL DEXMEDATOMEDINE VERSUS NALBUPHINE AS AN ADDITIVE WITH HYPERBARIC BUPIVACAINE IN LOWER LIMB ORTHOPAEDIC SURGERIES 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
nil  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Kartik H Sangam 
Designation  Resident Doctor 
Affiliation  Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre 
Address  Anaesthesia Department, General OT complex, 2nd Floor Dhiraj Hsopital, Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre, Waghodia , Piparia, Vadodara

Vadodara
GUJARAT
391760
India 
Phone  08767272524  
Fax    
Email  kartik.svdu2022@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Nilesh Shah 
Designation  Professor 
Affiliation  Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre 
Address  Anaesthesia Department, General OT complex, 2nd Floor Dhiraj Hsopital, Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre, Waghodia , Piparia, Vadodara

Vadodara
GUJARAT
391760
India 
Phone  9825038233  
Fax    
Email  nileshshah730@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Nilesh Shah 
Designation  Professor 
Affiliation  Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre 
Address  Anaesthesia Department, General OT complex, 2nd Floor Dhiraj Hsopital, Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre, Waghodia , Piparia, Vadodara

Vadodara
GUJARAT
391760
India 
Phone  9825038233  
Fax    
Email  nileshshah730@gmail.com  
 
Source of Monetary or Material Support  
nil 
 
Primary Sponsor  
Name  Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre 
Address  Waghodia, Pipariya, vadodara, Gujarat, india- 391760 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Kartik H Sangam  Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre  Anaesthesia Department, General OT complex, 2nd Floor Dhiraj Hsopital, Smt. Bhikiben Kanjibhai Shah Medical Institute and research Centre, Waghodia , Piparia, Vadodara
Vadodara
GUJARAT 
08767272524

kartik.svdu2022@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
SUMANDEEP VIDYAPEETH INSTITUTIONAL ETHICS COMMITTEE  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: M160||Bilateral primary osteoarthritis of hip, (2) ICD-10 Condition: M170||Bilateral primary osteoarthritis of knee, (3) ICD-10 Condition: M171||Unilateral primary osteoarthritisof knee,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  inj. dexmedatomedine 10 mcg intracthecally with hyperbaric bupivacaine  inj. dexmedatomedine 10 mcg intrathecally as an additive to inj. bupivcaine hyperbaric to compare the hemodynamic stabilty and post operative analgesia Dose - 10MCG Route - Intrathecally Duration- Till adminstration of Rescue analgesia 
Comparator Agent  inj. nalbuphine 1 mg intrathecally  inj nalbuphine 1 mg as additive to hyperbaric bupivacine 3 cc intrathecally to comapre hemodynamic stability and post operative analegsia Dose - 1mg Route - Intrathecally Duration- Till adminstration of Rescue analgesia 
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Patients willing to sign the informed written consent.
Patients of ASA Grade I and II of either gender Under Spinal anaesthesia for elective pelvic and lower limb surgeries
Aged 20 - 60 years.
No known history of allergy, sensitivity to local anaesthetics of the amide group and other drugs used for this study.
 
 
ExclusionCriteria 
Details  Patient refusal.
Patient not NIL by mouth.
History of seizure disorder.
Known allergy to trial drugs.
Patients with neurological disorders and neuropathies or receiving
medications known to influence neuromuscular junction.
ASA III, IV, V Patients.
Patient with prior pre-existing Comorbidities (Heart diseases,
Respiratory disease, Kidney diseases, known fetal abnormalities)
Pregnant females
Failed spinal anesthesia converted to general anesthesia
Any contraindication to Spinal Anaesthesia (local site infection,
spine deformity, clotting abnormalities. Patients fulfilling above
inclusion criteria are taken for study. 
 
Method of Generating Random Sequence   Coin toss, Lottery, toss of dice, shuffling cards etc 
Method of Concealment   Alternation 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
to Compare efficacy of dexmedatomedine and nalbuphine in blunting hemodynamic response and post operative analesgia in patient recieving
Spinal anaesthesia in lower limb orthopedic surgeries 
to Compare efficacy of dexmedatomedine and nalbuphine in blunting hemodynamic response and post operative analesgia in patient recieving
Spinal anaesthesia in lower limb orthopedic surgeries
Baseline
0 min
2 mins
5 mins
10 mins
20 mins
30 mins
45 mins
60 mins
90 mins
120 mins
150 mins
180 mins 
 
Secondary Outcome  
Outcome  TimePoints 
to compare duration of post operative analgesia in group dexmedatomedine & group nalbuphine  time at which rescue analgesia was given
Vas Score at induction
At 4 hours
6 hours
8 hours
Or anytime between when Vas Score More then 4 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "0"
Final Enrollment numbers achieved (India)="60" 
Phase of Trial   N/A 
Date of First Enrollment (India)   03/02/2025 
Date of Study Completion (India) 10/06/2025 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

INTRODUCTION:- Spinal anesthesia with hyperbaric bupivacaine 0.5%(heavy) is a popular method however there is a disadvantage of its short half-life. To overcome this disadvantage there is a constant search for an ideal adjuvant. Initially, opioids like fentanyl and buprenorphine were tried. Opioids reduce the toxicity and adverse cardiovascular effects of local anesthetics, however, this type of combination brings about additional undesirable problems like itching, nausea and vomiting and /or respiratory depression.

AIM:-,

Aim of this study is to compare the efficacy of Dexmedetomidine and Nalbuphine used as additive to bupivacaine in subarachnoid block in lower limb orthopedic surgeries

OBJECTIVES:-

TO COMPARE

Onset , duration of sensory and motor blockade

Sedation of patients.

The hemodynamic changes in (HR, BP, SpO2 and RR )

Duration of absolute analgesia and effective analgesia.

The requirement of a number of rescue analgesia.

The side effects/ Complications.

MATERIALS AND METHODOLOGY

 All the patients aged between 20 to 60 years old belonging to the American Society of Anesthesiologists (ASA) grade I or II undergoing elective lower limb Orthopedic surgery will be taken for the study. Written and informed consent will be taken from all the selected patients. 

Sunarachnoid Block Will be given in 2 different Groups of 30 each.


 
Close